SCHEMBL5243229

SCHEMBL5243229

O=S(=O)(Nc1cccc2ccccc12)c1ccc(Cl)c2nonc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
MAPT P10636 2/20 0.70
LMNA P02545 1/20 0.70
GAA P10253 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
PFKFB3 Q16875 1/20 0.51
RECQL P46063 1/20 0.49
RORA P35398 1/20 0.48
RORC P51449 1/20 0.48
NR1H2 P55055 1/20 0.48
POLB P06746 2/20 0.48
GFER P55789 1/20 0.48
SLC40A1 Q9NP59 3/20 0.46
KEAP1 Q14145 1/20 0.44
MCL1 Q07820 1/20 0.44
CASP6 P55212 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5280769 0.86 ALDH1A1 (0.53) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5243132 0.85 ALDH1A1 (0.51) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5293747 0.83 HKDC1 (0.53) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5244185 0.82 RORA (0.50) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5244817 0.82 RORA (0.53) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL8145375 0.82 RORA (0.53) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5242901 0.81 ALDH1A1 (0.58) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5282982 0.80 PIK3CD (0.52) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL5246500 0.79 DNMT1 (0.50) ALDH1A1MAPTLMNAGAAL3MBTL1
SCHEMBL6396349 0.79 ALDH1A1 (0.45) ALDH1A1MAPTLMNAGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP ALDH1A1 2627/4885MAPT 1681/4885LMNA 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.